Outlook Therapeutics, Inc. — Director's Dealing 2021

Feb 25, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Outlook Therapeutics, Inc. (OTLK)
CIK: 0001649989
Period of Report: 2021-02-23

Reporting Person: Evanson Jeff (Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-23	Common Stock	S	8554	$2.088	Disposed	1141930	Direct

Footnotes

F1: These shares were sold to cover taxes upon lapse of Issuer's repurchase right as to 25% of the shares as provided in that certain Consulting Agreement dated January 27, 2020.